1. Home
  2. AGIO vs UPBD Comparison

AGIO vs UPBD Comparison

Compare AGIO & UPBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • UPBD
  • Stock Information
  • Founded
  • AGIO 2007
  • UPBD 1986
  • Country
  • AGIO United States
  • UPBD United States
  • Employees
  • AGIO N/A
  • UPBD N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • UPBD Diversified Commercial Services
  • Sector
  • AGIO Health Care
  • UPBD Consumer Discretionary
  • Exchange
  • AGIO Nasdaq
  • UPBD Nasdaq
  • Market Cap
  • AGIO 1.4B
  • UPBD 1.2B
  • IPO Year
  • AGIO 2013
  • UPBD 1995
  • Fundamental
  • Price
  • AGIO $27.32
  • UPBD $23.66
  • Analyst Decision
  • AGIO Buy
  • UPBD Buy
  • Analyst Count
  • AGIO 8
  • UPBD 5
  • Target Price
  • AGIO $56.00
  • UPBD $36.60
  • AVG Volume (30 Days)
  • AGIO 524.5K
  • UPBD 570.7K
  • Earning Date
  • AGIO 05-01-2025
  • UPBD 05-01-2025
  • Dividend Yield
  • AGIO N/A
  • UPBD 6.59%
  • EPS Growth
  • AGIO N/A
  • UPBD N/A
  • EPS
  • AGIO 11.45
  • UPBD 2.13
  • Revenue
  • AGIO $37,035,000.00
  • UPBD $4,400,960,000.00
  • Revenue This Year
  • AGIO $40.62
  • UPBD $8.37
  • Revenue Next Year
  • AGIO $216.26
  • UPBD $6.79
  • P/E Ratio
  • AGIO $2.39
  • UPBD $11.13
  • Revenue Growth
  • AGIO 25.96
  • UPBD 8.07
  • 52 Week Low
  • AGIO $23.42
  • UPBD $19.68
  • 52 Week High
  • AGIO $62.58
  • UPBD $38.72
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 41.34
  • UPBD 56.84
  • Support Level
  • AGIO $27.78
  • UPBD $22.99
  • Resistance Level
  • AGIO $31.55
  • UPBD $24.60
  • Average True Range (ATR)
  • AGIO 1.38
  • UPBD 0.91
  • MACD
  • AGIO -0.03
  • UPBD 0.47
  • Stochastic Oscillator
  • AGIO 2.98
  • UPBD 79.40

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About UPBD Upbound Group Inc.

Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has three operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.

Share on Social Networks: